Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 16th Preview)
-
FDA approval – first-in-class CELMoDs expansion in multiple myeloma
Bristol Myers Squibb won U.S. FDA accelerated approval for Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj, plus dexamethasone, for adults with advanced multiple myeloma after at least one prior line of therapy. The clearance marks the debut of a new class of cancer drugs called CELMoDs, which are designed to target malignant cells using the body’s protein degradation machinery. The approval also uses minimal residual disease (MRD)-negative status as a more sensitive remission measure. Bristol Myers previously highlighted Phase 3 data showing higher MRD-negative rates with Zenbexus-based regimens versus comparators. The company is expected to report additional results in the coming months and is also testing Zenbexus in studies including maintenance settings. The FDA’s decision supports Zenbexus’ role as a franchise successor amid increasing generic pressure in multiple myeloma and sets up additional combination opportunities in the second-line space.
-
Oncology trial – oncolytic immunotherapy achieves high complete response in BCG-unresponsive NMIBC
Cretostimogene grenadenorepvec delivered complete responses in three-quarters of patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer in the phase III BOND-003 Cohort C trial, with most treatment-related adverse events reported as mild and transient. In the international, single-arm study reported in The Lancet Oncology by Tyson et al., 83 of 110 evaluable patients (75%) achieved complete response at any time after a median follow-up of 25.8 months. The result exceeded a prespecified historical benchmark of 20%. Responses appeared to deepen after re-induction, with 14 complete responses occurring post–second induction course, and durability reported at 46% complete response at 12 months and 42% maintaining complete response at 24 months. The therapy is administered intravesically once weekly for six weeks, with options for re-induction and maintenance for responders. The trial’s performance and safety profile add momentum for intravesical oncolytic approaches in a segment with limited effective options.
-
Biotech funding – new stealth launch for autoimmune platform-backed by Deerfield
Boulevard Bio emerged from stealth with about $65 million in launch financing to develop multi-specific antibody therapies for B cell-driven autoimmune diseases, backed entirely by Deerfield Management affiliates. The clinical-stage company is advancing three programs built around a precision immunology platform, with its lead candidate BLVD101 a bispecific antibody targeting BAFF and APRIL. The company is initially evaluating BLVD101 in IgA nephropathy. Boulevard’s early dosing strategy emphasizes potential quarterly administration, reflecting its goal to reduce treatment burden relative to more frequent antibody regimens. Interim Phase I data were cited as supporting the possibility of once-every-twelve-weeks dosing. Deerfield structured Boulevard’s development through its internal therapeutics engine, Deerfield Discovery and Development (3DC), spanning discovery through early clinical before spinning out as an independent entity. The launch financing signals continued appetite for protein engineering and functional B cell targeting in chronic immune-mediated indications.
-
Regulatory & commercial – OraSure withdraws FDA submission for CT/NG test, rewires milestone economics
OraSure Technologies withdrew its FDA 510(k) and CLIA waiver submission for its InteliQuick CT/NG point-of-care molecular test after discussions with the agency, pushing the expected clearance timeline out to beyond end of 2026. The withdrawal is tied to milestone payment terms in OraSure’s acquisition of Sherlock Biosciences from late 2024. OraSure said it will miss its targeted 2026 launch, reducing contingency milestone-related income and setting its liability for the milestones to zero. The test uses isothermal nucleic acid amplification to detect Chlamydia trachomatis and Neisseria gonorrhoeae in about 30 minutes for point-of-care and at-home settings. Company leadership told investors it remains confident the test performs well, while management flagged incremental costs tied to a future resubmission. The change highlights how FDA interactions can directly affect deal economics and commercialization timing.
-
Biotech pipeline – Capricor seeks FDA review after advisory vote for deramiocel in Duchenne
Capricor said it will ask the FDA to review additional data for deramiocel after a prior negative FDA advisory committee vote, aiming to improve the company’s chances for approval in a narrower Duchenne muscular dystrophy setting. The company framed its next step around submitting further analyses and information following the advisory outcome, which previously derailed a proposed approval pathway focused on specific endpoints and indications. Capricor’s position reflects how label language and endpoint strategy remain pivotal in cell therapy regulatory decisions for muscular dystrophies, where benefit-risk assessments depend heavily on clinically meaningful functional measures. The update comes as investors react to renewed prospects and as Capricor continues efforts to align its submission with the FDA’s expectations for its Phase III HOPE-3-based program.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.